Rhythm Pharmaceuticals, Inc.
RYTM
$93.72
$2.412.64%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 217.17M | 189.76M | 174.33M | 156.29M | 136.86M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 217.17M | 189.76M | 174.33M | 156.29M | 136.86M |
| Cost of Revenue | 23.00M | 19.49M | 18.48M | 16.81M | 14.21M |
| Gross Profit | 194.16M | 170.27M | 155.86M | 139.48M | 122.65M |
| SG&A Expenses | 219.44M | 194.94M | 175.59M | 158.54M | 149.01M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 414.54M | 381.77M | 360.54M | 333.73M | 309.49M |
| Operating Income | -197.37M | -192.02M | -186.21M | -177.44M | -172.62M |
| Income Before Tax | -201.72M | -196.04M | -191.89M | -183.08M | -168.57M |
| Income Tax Expenses | 962.00K | 497.00K | 438.00K | -17.00K | 125.00K |
| Earnings from Continuing Operations | -202.68 | -196.54 | -192.33 | -183.06 | -168.69 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -202.68M | -196.54M | -192.33M | -183.06M | -168.69M |
| EBIT | -197.37M | -192.02M | -186.21M | -177.44M | -172.62M |
| EBITDA | -196.17M | -190.68M | -184.76M | -175.91M | -171.08M |
| EPS Basic | -3.14 | -3.11 | -3.10 | -3.02 | -2.82 |
| Normalized Basic EPS | -1.90 | -1.89 | -1.88 | -1.83 | -1.80 |
| EPS Diluted | -3.14 | -3.11 | -3.10 | -3.02 | -2.82 |
| Normalized Diluted EPS | -1.90 | -1.89 | -1.88 | -1.83 | -1.80 |
| Average Basic Shares Outstanding | 264.80M | 259.88M | 254.60M | 249.56M | 246.89M |
| Average Diluted Shares Outstanding | 264.80M | 259.88M | 254.60M | 249.56M | 246.89M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |